Institut Maju Riset dan Inovasi

Institut Maju Riset dan Inovasi (IMRI) is an Indonesian biotechnology research organization dedicated to the development of advanced medical therapies and innovative healthcare solutions. The institute is most notably recognized for its development of "Vaksin Nusantara," a personalized dendritic cell-based vaccine platform initially targeted at COVID-19. IMRI's research portfolio extends into regenerative medicine and oncology, utilizing cell-based modalities to treat complex diseases. The organization operates through strategic collaborations with Indonesian military and government hospitals, such as RSPAD Gatot Soebroto, to facilitate clinical research. By focusing on personalized medicine, IMRI aims to provide alternative therapeutic options tailored to individual patient immune profiles. The institute continues to explore the application of its dendritic cell platform for various infectious diseases and solid tumors.